Navigation Links
Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
Date:8/11/2011

THE WOODLANDS, Texas, Aug. 11, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the Wedbush 2011 Life Sciences Management Access Conference on Tuesday, August 16, 2011 at 1:15 p.m. Eastern Time in New York City.  Dr. Sands will provide an overview on Lexicon's clinical development programs and milestones.

A live webcast of the event may be accessed on Lexicon's corporate website at www.lexpharma.com.  An archived version of the webcast will be available for 30 days after the event on the company's website.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
2. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
3. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
4. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
5. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
6. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
7. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
8. Lexicon to Provide First Quarter 2011 Financial Results
9. Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
10. Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
11. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... , Aug. 7, 2017 Zimmer Biomet Holdings, ... healthcare, today announced that its Board of Directors has approved ... the third quarter of 2017. ... paid on or about October 27, 2017 to stockholders of ... 2017.  Future declarations of dividends are subject to approval of ...
(Date:8/7/2017)...  Endo International plc (NASDAQ: ENDP ) ... all known U.S. mesh product liability claims and that ... remaining U.S. claims at reasonable values. Under the agreements, ... quarter of 2017 and continuing through the fourth quarter ... results, the Company intends to increase its mesh product ...
(Date:8/3/2017)... 2017  Opioid addiction and other drugs of abuse, ... and threatening outcomes, were problems taken on directly as ... that support them, met this week. This according to ... drugs of abuse, procalcitonin and acute kidney injury were ... 69th meeting in San Diego, CA. ...
Breaking Medicine Technology:
(Date:8/22/2017)... , ... August 22, 2017 , ... Five Star Glass is new to the Texas ... and replacement of auto glass for most makes and models, in Grand Prairie, TX, located ... , They have been a family owned business for the past 40 years with ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... “Wilderness Voices”: ... of world travel. “Wilderness Voices” is the creation of published author, Martha McKown, ... Martha McKown was inspired as a very young child when her older sisters studied ...
(Date:8/22/2017)... ... , ... “Covert Awakening”: Walid’s spiritual journey from Islamic terrorist ... a consultant for the Intelligence Community. For more than ten years, she ... region. Julianne has written hundreds of reports for the US government analyzing ...
(Date:8/22/2017)... North Carolina (PRWEB) , ... August 22, 2017 ... ... strategic advisor. Mr. Stewart is the Founder and Managing Member for t4 Leadership ... that have become critical to his definition of “success”: physician leadership development, servant ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Call Of Spiritual Duty”: a ... creation of published author, C.S. Lizarde. Growing up on the streets of North ... When Carlos began to apply the Biblical keys to his life, he noticed immediately ...
Breaking Medicine News(10 mins):